Parts matching “AAV9” · all types
Breakthrough serotype capable of crossing the blood-brain barrier systemically. Revolutionized CNS gene therapy with broad neuronal and glial transduction. FDA-approved for spinal muscular atrophy.
AAV9 variant with modified tropism profile for balanced tissue distribution with focus on muscle and cardiac tissue.
First-generation blood-brain barrier penetrating AAV variant evolved from AAV9 using CREATE methodology. Mouse strain-specific due to LY6A receptor dependence.
Rhesus macaque-derived serotype with strong liver and skeletal muscle tropism. Part of the expanded AAV toolkit from non-human primate tissue screening.
The inverted terminal repeat of adeno-associated virus 2, the cis-acting element at each end of an AAV genome. A vector keeps the two copies as the borders of the transfer unit, and the AAV Rep proteins act on them to replicate and package what lies between.
Engineered AAV2 capsid with 100-fold enhanced retrograde transport efficiency, delivering transgenes to projection neurons by infecting axon terminals and trafficking to the soma. Does not cross synapses, enabling input-specific circuit labeling without contamination from neighboring pathways. Standard vector for optogenetics, chemogenetics, and long-range neural connectivity studies.
Human serotype with unique hepatocyte growth factor receptor (HGFR) usage, conferring selective human hepatocyte and cancer cell tropism. Species-specific characteristics.
Engineered AAV2 variant selected through directed evolution in human hepatocyte xenograft mice. Contains a seven-amino acid insertion at position 588 in the capsid.
Natural serotype with unique receptor usage and distinct tropism profile. Notable for lower pre-existing immunity and efficient CNS transduction.
First AAV serotype discovered and most extensively characterized. Gold standard for AAV research with broad tissue tropism. Foundation for most engineered AAV variants.
Highly efficient liver-tropic serotype widely used in clinical hepatic gene therapy. Discovered from rhesus macaque tissue. Superior liver transduction versus AAV2.
Natural AAV serotype with strong skeletal and cardiac muscle tropism. One of the earliest discovered and most clinically relevant serotypes for muscle-directed gene therapy.
AAV2 variant engineered for enhanced CNS penetration through rational capsid modification with improved neuronal transduction.
Liver-detargeted AAV9 variant engineered to reduce hepatic uptake while maintaining cardiac and skeletal muscle transduction.
Recombinant AAV capsid of AAV1, 6, 7 and 8 origin, selected from a shuffled AAV1-9 capsid library by in vivo panning in mice for striated muscle targeting. After systemic delivery, myocardium shows the highest expression among tissues tested.
First successful chimeric AAV created through DNA family shuffling of AAV2, AAV8, and AAV9. Proof-of-concept for rational capsid engineering and hybrid vector design.
Peptide-displaying AAV9 capsid variant (AAV9P1) carrying the 7-mer peptide P1 (RGDLGLS) on the capsid surface. Identified in a barcoded in vivo screen of 183 pre-selected capsids in mice. Transduces skeletal muscle, diaphragm and heart after intravenous injection, with lower liver transduction than AAV9.
BBB-penetrating AAV9 variant engineered through peptide-display library screening. Uses carbonic anhydrase IV receptor but shows species-limited efficacy.
Natural serotype with exceptionally strong skeletal muscle, cardiac muscle, and lung tropism. Clinically relevant for muscle and airway diseases.
Peptide-displaying chimeric AAV capsid (AAVS10P1) made by grafting the AAVMYO peptide P1 (RGDLGLS) into AAVS10, a muscle-selected capsid from DNA family shuffling of AAV1, AAV6, AAV8 and AAV9. Targets skeletal muscle, diaphragm and heart in mice with strong liver detargeting.
Third-generation CREATE variant engineered for enhanced cardiac tropism with maintained BBB penetration capability.
Human tissue-derived serotype with distinct CNS tropism patterns. Part of expanded human AAV diversity screen showing serotype-specific brain region targeting.
Peptide-displaying chimeric AAV capsid (AAVS1P1) made by grafting the AAVMYO peptide P1 (RGDLGLS) into AAVS1, a muscle-selected capsid from DNA family shuffling of AAV1, AAV6, AAV8 and AAV9. Targets skeletal muscle, diaphragm and heart in mice with strong liver detargeting.
Engineered AAV9 variant with 10-fold improved cardiac-to-liver transduction ratio for heart-targeted gene therapy.